Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT02735980

Public ClinicalTrials.gov record NCT02735980. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 8:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the association between tumor response and the participant's perceived quality of life.

Study identification

NCT ID
NCT02735980
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
133 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 10, 2016
Primary completion
Jul 30, 2017
Completion
Feb 11, 2019
Last update posted
Mar 16, 2020

2016 – 2019

United States locations

U.S. sites
14
U.S. states
9
U.S. cities
12
Facility City State ZIP Site status
Highlands Oncology Group Fayetteville Arkansas 72703
Yale University School of Medicine New Haven Connecticut 06520
Georgetown University Medical Center Washington D.C. District of Columbia 20007
Florida Cancer Specialists Fort Myers Florida 33908
Florida Cancer Specialists and Research Institute St. Petersburg Florida 33705
Massachusetts General Hospital Danvers Massachusetts 01923
Washington University Medical Center St Louis Missouri 63110
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03756-0001
Chattanooga Oncology Hematology Associates Chattanooga Tennessee 37404
Sarah Cannon Cancer Center Nashville Tennessee 37203
Tennessee Oncology PLLC Nashville Tennessee 37203
Vanderbilt University Medical Center Nashville Tennessee 37232-6307
The Center for Cancer and Blood Disorders Fort Worth Texas 76104
University of Texas MD Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02735980, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 16, 2020 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02735980 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →